Amedeo Smart

Free Medical Literature Service

 

Amedeo

Diabetes
  Free Subscription

Articles published in
J Am Coll Cardiol
    April 2024
  1. KITTIPIBUL V, Cox ZL, Chesdachai S, Fiuzat M, et al
    Genitourinary Tract Infections in Patients Taking SGLT2 Inhibitors: JACC Review Topic of the Week.
    J Am Coll Cardiol. 2024;83:1568-1578.
    >> Share

  2. WONG ND, Fan W, Hu X, Ballantyne C, et al
    Lipoprotein(a) and Long-Term Cardiovascular Risk in a Multi-Ethnic Pooled Prospective Cohort.
    J Am Coll Cardiol. 2024;83:1511-1525.
    >> Share

  3. BURCHILL LJ, Jain CC, Miranda WR
    Advancing New Solutions for Adult Congenital Heart Disease-Related Heart Failure.
    J Am Coll Cardiol. 2024;83:1415-1417.
    >> Share

  4. PACKER M
    SGLT2 Inhibition: Neither a Diuretic nor a Natriuretic.
    J Am Coll Cardiol. 2024;83:1399-1402.
    >> Share

  5. MARTON A, Saffari SE, Rauh M, Sun RN, et al
    Water Conservation Overrides Osmotic Diuresis During SGLT2 Inhibition in Patients With Heart Failure.
    J Am Coll Cardiol. 2024;83:1386-1398.
    >> Share

  6. NEIJENHUIS RML, MacDonald ST, Zemrak F, Mertens BJA, et al
    Effect of Sodium-Glucose Cotransporter 2 Inhibitors in Adults With Congenital Heart Disease.
    J Am Coll Cardiol. 2024;83:1403-1414.
    >> Share

  7. COSTANZO MR, Januzzi JL
    Early SGLT2 Inhibitors in Acute Heart Failure: Safe Diuretic-Sparing Strategy.
    J Am Coll Cardiol. 2024;83:1307-1309.
    >> Share

  8. JANUZZI JL JR, Butler J, Del Prato S, Ezekowitz JA, et al
    Randomized Trial of a Selective Aldose Reductase Inhibitor in Patients With Diabetic Cardiomyopathy.
    J Am Coll Cardiol. 2024 Apr 3:S0735-1097(24)06613.
    >> Share

    March 2024
  9. CHATUR S, Vaduganathan M, Claggett B, Solomon SD, et al
    Reply: Rethinking eGFR Comparisons in SGLT2 Inhibitor Research.
    J Am Coll Cardiol. 2024;83:e89.
    >> Share

  10. OHSHIRO Y
    Rethinking eGFR Comparisons in SGLT2 Inhibitor Research.
    J Am Coll Cardiol. 2024;83:e87.
    >> Share

  11. HANSEN MK, Olesen KKW, Gyldenkerne C, Thrane PG, et al
    Eligibility for and Preventive Potential of Semaglutide in Overweight and Obese Patients With Myocardial Infarction.
    J Am Coll Cardiol. 2024;83:956-958.
    >> Share

    February 2024
  12. KRISHNARAJ A, Bakbak E, Teoh H, Pan Y, et al
    Vascular Regenerative Cell Deficiencies in South Asian Adults.
    J Am Coll Cardiol. 2024;83:755-769.
    >> Share

  13. SCHIAVON CA, Cavalcanti AB, Oliveira JD, Machado RHV, et al
    Randomized Trial of Effect of Bariatric Surgery on Blood Pressure After 5 Years.
    J Am Coll Cardiol. 2024;83:637-648.
    >> Share

    January 2024
  14. PACKER M
    Hyperuricemia and Gout Reduction by SGLT2 Inhibitors in Diabetes and Heart Failure: JACC Review Topic of the Week.
    J Am Coll Cardiol. 2024;83:371-381.
    >> Share

    November 2023
  15. VADUGANATHAN M, Ostrominski JW
    Glucagon-Like Peptide-1 Receptor Agonists in Heart Failure: STEPping Across the Ejection Fraction Divide.
    J Am Coll Cardiol. 2023;82:2097-2100.
    >> Share

  16. COCA SG
    SGLT2i and Deterioration of Kidney Function in Heart Failure: Another Demonstration for Tolerance of "Hypercreatininemia".
    J Am Coll Cardiol. 2023;82:1864-1867.
    >> Share

  17. FONAROW GC, Mohebi R
    Sotagliflozin Efficacy Irrespective of Hemoglobin A1c Level.
    J Am Coll Cardiol. 2023;82:1852-1853.
    >> Share

  18. AGGARWAL R, Bhatt DL, Szarek M, Cannon CP, et al
    Efficacy of Sotagliflozin in Adults With Type 2 Diabetes in Relation to Baseline Hemoglobin A1c.
    J Am Coll Cardiol. 2023;82:1842-1851.
    >> Share

    October 2023
  19. BLAHA MJ, Khorsandi M
    Type 2 Diabetes Mellitus: Now in the Cardiologist's Wheelhouse.
    J Am Coll Cardiol. 2023;82:1595-1597.
    >> Share

  20. GYLDENKERNE C, Mortensen MB, Kahlert J, Thrane PG, et al
    10-Year Cardiovascular Risk in Patients With Newly Diagnosed Type 2 Diabetes Mellitus.
    J Am Coll Cardiol. 2023;82:1583-1594.
    >> Share

  21. OHSHIRO Y
    Empagliflozin in Patients With Heart Failure: Efficacy and Safety Concerns Across Kidney Risk Categories.
    J Am Coll Cardiol. 2023;82:e133.
    >> Share

    August 2023
  22. CHATUR S, Vaduganathan M, Claggett BL, Mc Causland FR, et al
    Dapagliflozin in Patients with Heart Failure and Deterioration in Estimated Glomerular Filtration Rate to <25ml/min/1.73m(2).
    J Am Coll Cardiol. 2023 Aug 23:S0735-1097(23)06532.
    >> Share

  23. ARODA VR, Billings LK
    GLP-1 RA and SGLT2 Inhibitors: In Harmony for Organ Protection.
    J Am Coll Cardiol. 2023;82:526-528.
    >> Share

  24. NEVES JS, Borges-Canha M, Vasques-Novoa F, Green JB, et al
    GLP-1 Receptor Agonist Therapy With and Without SGLT2 Inhibitors in Patients With Type 2 Diabetes.
    J Am Coll Cardiol. 2023;82:517-525.
    >> Share

  25. KONDO T, Wang X, Yang M, Jhund PS, et al
    Efficacy of Dapagliflozin According to Geographic Location of Patients With Heart Failure.
    J Am Coll Cardiol. 2023 Aug 2:S0735-1097(23)05964.
    >> Share

    July 2023
  26. MORALES J, Handelsman Y
    Cardiovascular Outcomes in Patients With Diabetes and Kidney Disease: JACC Review Topic of the Week.
    J Am Coll Cardiol. 2023;82:161-170.
    >> Share

    June 2023
  27. BRUMMEL K, Eagle K
    An Atherothrombotic Risk Score for Patients With Diabetes: Useful Tool or More of the Same?
    J Am Coll Cardiol. 2023;81:2403-2405.
    >> Share

  28. BERG DD, Moura FA, Bellavia A, Scirica BM, et al
    Assessment of Atherothrombotic Risk in Patients With Type 2 Diabetes Mellitus.
    J Am Coll Cardiol. 2023;81:2391-2402.
    >> Share

  29. WIVIOTT SD, Berg DD
    SGLT2 Inhibitors Reduce Heart Failure Hospitalization and Cardiovascular Death: Clarity and Consistency.
    J Am Coll Cardiol. 2023;81:2388-2390.
    >> Share

  30. USMAN MS, Siddiqi TJ, Anker SD, Bakris GL, et al
    Effect of SGLT2 Inhibitors on Cardiovascular Outcomes Across Various Patient Populations.
    J Am Coll Cardiol. 2023;81:2377-2387.
    >> Share

    May 2023
  31. SUKUMAR S, Wasfy JH, Januzzi JL, Peppercorn J, et al
    Financial Toxicity of Medical Management of Heart Failure: JACC Review Topic of the Week.
    J Am Coll Cardiol. 2023;81:2043-2055.
    >> Share

  32. KRISTENSEN SL, Jensen J, Schou M
    SGLT2 Inhibitors in Patients With Heart Failure and Chronic Kidney Disease: Jigsaw Falling Into Place.
    J Am Coll Cardiol. 2023;81:1915-1917.
    >> Share

  33. BUTLER J, Packer M, Siddiqi TJ, Bohm M, et al
    Efficacy of Empagliflozin in Patients With Heart Failure Across Kidney Risk Categories.
    J Am Coll Cardiol. 2023;81:1902-1914.
    >> Share

    April 2023
  34. VERMA S, Bhatt DL, Dhingra NK, Steg PG, et al
    Time to Benefit With Sotagliflozin in Patients With Worsening Heart Failure.
    J Am Coll Cardiol. 2023;81:1546-1549.
    >> Share

  35. KHAN H, Kunutsor SK
    Nonsteroidal Anti-Inflammatory Drugs and Type 2 Diabetes: A Recipe for Heart Failure?
    J Am Coll Cardiol. 2023;81:1471-1473.
    >> Share

  36. HOLT A, Strange JE, Nouhravesh N, Nielsen SK, et al
    Heart Failure Following Anti-Inflammatory Medications in Patients With Type 2 Diabetes Mellitus.
    J Am Coll Cardiol. 2023;81:1459-1470.
    >> Share

    January 2023
  37. TAGGART C, Monterrubio-Gomez K, Roos A, Boeddinghaus J, et al
    Improving Risk Stratification for Patients With Type 2 Myocardial Infarction.
    J Am Coll Cardiol. 2023;81:156-168.
    >> Share

    December 2022
  38. AN P, Wan S, Luo Y, Luo J, et al
    Micronutrient Supplementation to Reduce Cardiovascular Risk.
    J Am Coll Cardiol. 2022;80:2269-2285.
    >> Share

  39. HATHAWAY QA, Yanamala N, Siva NK, Adjeroh DA, et al
    Ultrasonic Texture Features for Assessing Cardiac Remodeling and Dysfunction.
    J Am Coll Cardiol. 2022;80:2187-2201.
    >> Share

    November 2022
  40. AL-KINDI S, Motairek I, Janus S, Deo S, et al
    Time-Varying Cardiovascular Effects of Finerenone in Diabetic Kidney Disease: Insights From FIDELIO-DKD and FIGARO-DKD Trials.
    J Am Coll Cardiol. 2022;80:1855-1856.
    >> Share

  41. NASSIF ME, Januzzi JL Jr
    Implementing Sodium-Glucose Cotransporter-2 Inhibitor Therapy for Heart Failure: What Is the Message to DELIVER?
    J Am Coll Cardiol. 2022;80:1785-1787.
    >> Share

  42. VADUGANATHAN M, Claggett BL, Jhund P, de Boer RA, et al
    Estimated Long-Term Benefit of Dapagliflozin in Patients With Heart Failure.
    J Am Coll Cardiol. 2022;80:1775-1784.
    >> Share

  43. ZANNAD F
    Heart Failure and Kidney Disease in Type 2 Diabetes: 2 Sides of the Same Coin.
    J Am Coll Cardiol. 2022;80:1732-1734.
    >> Share

  44. SARRAJU A, Bakris G, Cannon CP, Cherney D, et al
    Cardiovascular Effects of Canagliflozin in Relation to Renal Function and Albuminuria.
    J Am Coll Cardiol. 2022;80:1721-1731.
    >> Share

    September 2022
  45. KERN MJ, Seto AH
    Does Diabetes Affect Angiographically Derived (QFR) Translesional Physiology?: Looking at the FAVOR III Diabetic Subset.
    J Am Coll Cardiol. 2022;80:1265-1267.
    >> Share

  46. JIN Z, Xu B, Yang X, Jia R, et al
    Coronary Intervention Guided by Quantitative Flow Ratio vs Angiography in Patients With or Without Diabetes.
    J Am Coll Cardiol. 2022;80:1254-1264.
    >> Share

  47. WANG N, Harris K, Hamet P, Harrap S, et al
    Cumulative Systolic Blood Pressure Load and Cardiovascular Risk in Patients With Diabetes.
    J Am Coll Cardiol. 2022;80:1147-1155.
    >> Share

    August 2022
  48. AHMAD T, Desai NR, Velazquez EJ
    SGLT2 Inhibitors Should Be Considered for All Patients With Heart Failure.
    J Am Coll Cardiol. 2022 Aug 26. pii: S0735-1097(22)05770.
    >> Share

  49. MOHEBI R, Chen C, Ibrahim NE, McCarthy CP, et al
    Cardiovascular Disease Projections in the United States Based on the 2020 Census Estimates.
    J Am Coll Cardiol. 2022;80:565-578.
    >> Share

    July 2022
  50. KOTTKE TE, Gupta AK, Thomas RJ
    Failing Cardiovascular Health: A Population Code Blue.
    J Am Coll Cardiol. 2022;80:152-154.
    >> Share

    June 2022
  51. FARIDI KF, Dayoub EJ, Ross JS, Dhruva SS, et al
    Medicare Coverage and Out-of-Pocket Costs of Quadruple Drug Therapy for Heart Failure.
    J Am Coll Cardiol. 2022;79:2516-2525.
    >> Share

  52. VERMA S, Pandey A, Bhatt DL
    Forecasting Heart Failure Risk in Diabetes.
    J Am Coll Cardiol. 2022;79:2294-2297.
    >> Share

  53. ECHOUFFO-TCHEUGUI JB, Ndumele CE, Zhang S, Florido R, et al
    Diabetes and Progression of Heart Failure: The Atherosclerosis Risk In Communities (ARIC) Study.
    J Am Coll Cardiol. 2022;79:2285-2293.
    >> Share

  54. HAUGE MG, Damm P, Kofoed KF, Ersboll AS, et al
    Early Coronary Atherosclerosis in Women With Previous Preeclampsia.
    J Am Coll Cardiol. 2022;79:2310-2321.
    >> Share

    May 2022
  55. UDELL JA, Jones WS, Petrie MC, Harrington J, et al
    Sodium Glucose Cotransporter-2 Inhibition for Acute Myocardial Infarction: JACC Review Topic of the Week.
    J Am Coll Cardiol. 2022;79:2058-2068.
    >> Share

  56. STUART JJ, Tanz LJ, Rimm EB, Spiegelman D, et al
    Cardiovascular Risk Factors Mediate the Long-Term Maternal Risk Associated With Hypertensive Disorders of Pregnancy.
    J Am Coll Cardiol. 2022;79:1901-1913.
    >> Share

  57. KELSEY MD, Nelson AJ, Green JB, Granger CB, et al
    Guidelines for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: JACC Guideline Comparison.
    J Am Coll Cardiol. 2022;79:1849-1857.
    >> Share

  58. BEHAN SA, Mulder H, Rockhold FW, Gutierrez JA, et al
    Impact of Polyvascular Disease and Diabetes on Limb and Cardiovascular Risk in Peripheral Artery Disease.
    J Am Coll Cardiol. 2022;79:1781-1783.
    >> Share

    April 2022
  59. REGENSTEINER JG, Reusch JEB
    Sex Differences in Cardiovascular Consequences of Hypertension, Obesity, and Diabetes: JACC Focus Seminar 4/7.
    J Am Coll Cardiol. 2022;79:1492-1505.
    >> Share

  60. TAKAHASHI K, Serruys PW, Fuster V, Farkouh ME, et al
    External Validation of the FREEDOM Score for Individualized Decision Making Between CABG and PCI.
    J Am Coll Cardiol. 2022;79:1458-1473.
    >> Share

    March 2022
  61. GHAZI L, Yamamoto Y, Riello RJ, Coronel-Moreno C, et al
    Electronic Alerts to Improve Heart Failure Therapy in Outpatient Practice: A Cluster Randomized Trial.
    J Am Coll Cardiol. 2022 Mar 19. pii: S0735-1097(22)04489.
    >> Share

    February 2022
  62. VADUGANATHAN M, Sattar N, Xu J, Butler J, et al
    Stress Cardiac Biomarkers, Cardiovascular and Renal Outcomes, and Response to Canagliflozin.
    J Am Coll Cardiol. 2022;79:432-444.
    >> Share

    January 2022
  63. VASAN RS, Enserro DM, Beiser AS, Xanthakis V, et al
    Lifetime Risk of Heart Failure Among Participants in the Framingham Study.
    J Am Coll Cardiol. 2022;79:250-263.
    >> Share

  64. VOLGMAN AS, Nair G, Lyubarova R, Merchant FM, et al
    Management of Atrial Fibrillation in Patients 75 Years and Older: JACC State-of-the-Art Review.
    J Am Coll Cardiol. 2022;79:166-179.
    >> Share

    December 2021
  65. JOSEPH JJ, Ortiz R, Acharya T, Golden SH, et al
    Cardiovascular Impact of Race and Ethnicity in Patients With Diabetes and Obesity: JACC Focus Seminar 2/9.
    J Am Coll Cardiol. 2021;78:2471-2482.
    >> Share

  66. LAWTON JS, Tamis-Holland JE, Bangalore S, Bates ER, et al
    2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.
    J Am Coll Cardiol. 2021 Dec 7. pii: S0735-1097(21)06157.
    >> Share

    November 2021
  67. RAO VN, Murray E, Butler J, Cooper LB, et al
    In-Hospital Initiation of Sodium-Glucose Cotransporter-2 Inhibitors for Heart Failure With Reduced Ejection Fraction.
    J Am Coll Cardiol. 2021;78:2004-2012.
    >> Share

    October 2021
  68. ARODA VR, Taub PR, Stanton AM
    Diabetes With Cardiomyopathy: At the Juncture of Knowledge and Prevention.
    J Am Coll Cardiol. 2021;78:1599-1602.
    >> Share

  69. SEGAR MW, Khan MS, Patel KV, Butler J, et al
    Prevalence and Prognostic Implications of Diabetes With Cardiomyopathy in Community-Dwelling Adults.
    J Am Coll Cardiol. 2021;78:1587-1598.
    >> Share

  70. ROSSELLO X, Ibanez B, Fuster V
    Reply: What Is Behind the HbA1c Value?
    J Am Coll Cardiol. 2021;78:e119.
    >> Share

  71. TANAKA A, Node K
    What Is Behind the HbA1c Value?
    J Am Coll Cardiol. 2021;78:e117.
    >> Share

    June 2021
  72. GRAHAM IM, Di Angelantonio E, Visseren F, De Bacquer D, et al
    Systematic Coronary Risk Evaluation (SCORE): JACC Focus Seminar 4/8.
    J Am Coll Cardiol. 2021;77:3046-3057.
    >> Share

    May 2021
  73. HONIGBERG MC, Zekavat SM, Pirruccello JP, Natarajan P, et al
    Cardiovascular and Kidney Outcomes across the Glycemic Spectrum: Insights from the UK Biobank.
    J Am Coll Cardiol. 2021 May 11. pii: S0735-1097(21)05045.
    >> Share

    March 2021
  74. PACKER M, Anker SD, Butler J, Filippatos G, et al
    Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload: EMPEROR-Reduced Trial.
    J Am Coll Cardiol. 2021;77:1381-1392.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016